Top

BY Scott Merville


An immunotherapy used against advanced non-small cell lung cancer is being tested at MD Anderson for a different job: preventing the disease from developing in people with pre-cancerous lung nodules.

The first-of-its-kind Phase II clinical trial is based on research into these precancerous growths by Jianjun Zhang, M.D., Ph.D., assistant professor of Thoracic/Head and Neck Medical Oncology.

How...

An immunotherapy clinical trial uses the immune checkpoint blockade drug pembrolizumab against precancerous growths to prevent their evolution to lung cancer.

BY Clayton Boldt, Ph.D.

November is Lung Cancer Awareness Month, and the third Thursday of each November is designated by the American Cancer Society as the Great...

BY Clayton Boldt, Ph. D.

Each year in the U.S., more than 50,000 people will be diagnosed with pancreatic cancer, which ranks around the 10th most common cancer type...

BY Jill Russell, Ph.D.

MD Anderson researchers have identified early genomic events that may lead to malignant transformation. They’ve found that tissue adjacent to tumors that appears to be pathologically normal may harbor cells with mutations that could lead to cancer.

“These findings provide important insights to the earliest changes that lead to malignancy and could help with early detection of cancer or even prevention,” says Paul Scheet, Ph.D....

The distribution along the genome of chromosomal alterations, contrasting the profile of normal-appearing adjacent-to-tumor (NAT) tissues and blood. (Click on image to enlarge.)

BY Meagan Raeke

The recent outbreak of lung injury and death associated with e-cigarettes and vaping has led to a renewed scrutiny of electronic nicotine...

BY Meagan Raeke

Despite the fact that the human papillomavirus (HPV) vaccine has been available in the U.S. for over 10 years and remains the only vaccine...

BY Meagan Raeke

A study from researchers at The University of Texas MD Anderson Cancer Center found that the prevalence of the types of oral human papillomavirus...

BY Clayton Boldt

Prostate cancer is the most common cancer diagnosed in American men, and the second leading cause of cancer death in men. While hormone-based...

BY Clayton R. Boldt, Ph.D.

MD Anderson Cancer Center researchers, together with collaborators from Mozambique, Brazil and the U.S., have been awarded a $5.1 million...

BY Clayton R. Boldt, Ph.D.

Many are aware of the importance of cancer research for the discovery of new therapies and treatment options, but perhaps less well-known...